Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 27;2(1):100194.
doi: 10.1016/j.jacadv.2022.100194. eCollection 2023 Jan.

Is Stent Thrombosis a Genetic Disease?

Guillaume Cayla  1 , Benoit Lattuca  2
Affiliations
Editorial

Is Stent Thrombosis a Genetic Disease?

Guillaume Cayla et al. JACC Adv. .
No abstract available

Keywords: genetics; percutaneous coronary intervention; stent thrombosis.

PubMed Disclaimer

Conflict of interest statement

Dr Cayla has received research grants, consultant fees, and lectures fees from Amgen, AstraZeneca, Abbott, Bayer, Biotronik, Bristol-Myers Squibb, Edwards, Microport, Medtronic, Pfizer, and Sanofi-Aventis. Dr Lattuca has received research grants from Biotronik, Daiichi Sankyo, Fédération Française de Cardiologie, Institute of CardioMetabolism, and Nutrition and Medtronic; and has received consultant fees from Abbott Vascular, Amarin, AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Medtronic, Novartis, Sanofi, and Terumo.

Figures

None
Graphical abstract
Figure 1
Figure 1
Better Comprehension of ST Mechanisms, Improvement of the Drugs and Stent Implantation Have Contributed to Considerably Reduced Rate of Both Early and Late ST to <1% ACS = acute coronary syndrome; BMS = bare-metal stent; CRF = chronic renal failure; DES = drug-eluting stent; LVEF = left ventricular ejection fraction.
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jacadv.2022.100172

References

    1. Serruys P.W., Strauss B.H., Beatt K.J., et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–17. - PubMed
    1. Mega J.L., Simon T., Collet J.-P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–1830. - PMC - PubMed
    1. Hulot J.-S., Collet J.-P., Cayla G., et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;4:422–428. - PubMed
    1. Wallentin L., James S., Storey R.F., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328. - PubMed
    1. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. - PubMed

Publication types

LinkOut - more resources